About: Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study
Creator	Sharma, S Khalid, M Waheed, M Rodriguez, D Siddiqui, S Agarwal, C Alliu, S Aslam, A Chukwuka, N Ehrlich, S Hashmi, A Henriquez-Felipe, C Le, J Malyshev, Y Mukhtar, O Rojas-Marte, G Shani, J Sharma, D
source	Medline; PMC
abstract	BACKGROUND: COVID-19 is an ongoing threat to society. Patients who develop the most severe forms of the disease have high mortality. The interleukin-6 inhibitor tocilizumab has the potential to improve outcomes in these patients by preventing the development of cytokine release storm. AIMS: To evaluate the outcomes of patients with severe COVID-19 disease treated with the interleukin-6 inhibitor tocilizumab. METHODS: We conducted a retrospective, case–control, single-center study in patients with severe to critical COVID-19 disease treated with tocilizumab. Disease severity was defined based on the amount of oxygen supplementation required. The primary endpoint was the overall mortality. Secondary endpoints were mortality in non-intubated patients and mortality in intubated patients. RESULTS: A total of 193 patients were included in the study. Ninety-six patients received tocilizumab, while 97 served as the control group. The mean age was 60 years. Patients over 65 years represented 43% of the population. More patients in the tocilizumab group reported fever, cough and shortness of breath (83%, 80% and 96% vs. 73%, 69% and 71%, respectively). There was a non-statistically significant lower mortality in the treatment group (52% vs. 62.1%, P = 0.09). When excluding intubated patients, there was statistically significant lower mortality in patients treated with tocilizumab (6% vs. 27%, P = 0.024). Bacteremia was more common in the control group (24% vs. 13%, P = 0.43), while fungemia was similar for both (3% vs. 4%, P = 0.72). CONCLUSION: Our study showed a non-statistically significant lower mortality in patients with severe to critical COVID-19 disease who received tocilizumab. When intubated patients were excluded, the use of tocilizumab was associated with lower mortality.
has issue date	2020-06-19(xsd:dateTime)
bibo:doi	10.1093/qjmed/hcaa206
bibo:pmid	32569363
has license	no-cc
sha1sum (hex)	fb89758af79fa1f1a3a68100d4eb11ab5ca87815
schema:url	https://doi.org/10.1093/qjmed/hcaa206
resource representing a document's title	Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study
has PubMed Central identifier	PMC7337835
has PubMed identifier	32569363
schema:publication	QJM
resource representing a document's body	covid:fb89758af79fa1f1a3a68100d4eb11ab5ca87815#body_text
is schema:about of	named entity 'treated' named entity 'severe' named entity 'control group' named entity 'treated' named entity 'patients' named entity 'total' named entity 'Outcomes' named entity 'BACTEREMIA' named entity 'COVID-19' named entity 'RETROSPECTIVE' named entity 'STORM' named entity 'development' named entity 'COVID-19' named entity 'mortality' named entity 'cough' named entity 'Bacteremia' named entity 'More' named entity 'high' named entity 'statistically' named entity 'critical' named entity 'cytokine' named entity 'served' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'treatment group' named entity 'tumor necrosis factor alpha' named entity 'global pandemic' named entity 'control group' named entity 'intubation' named entity 'bacteremia' named entity 'treatment group' named entity 'case series' named entity 'mortality rate' named entity 'cytokine storm' named entity 'COVID-19 disease' named entity 'comorbidities' named entity 'intubated' named entity 'shortness of breath' named entity 'tocilizumab' named entity 'clinical trials' named entity 'mortality rate' named entity 'diabetes' named entity 'bacterial infections' named entity 'composite endpoint' named entity 'face mask' named entity 'SPSS Inc.' named entity 'D-dimer' named entity 'case-control study' named entity 'recombinant' named entity 'treatment group' named entity 'polymerase chain reaction' named entity 'ICU' named entity 'exact test' named entity 'tocilizumab' named entity 'diabetes mellitus' named entity 'chronic lung disease' named entity 'tocilizumab' named entity 'control group' named entity 'intubated' named entity 'COVID-19 disease' named entity 'selection bias' named entity 'informed consent' named entity 'Bacteremia' named entity 'oxygen supplementation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software